Literature DB >> 1851588

Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients.

B Ringe1, R Pichlmayr, C Wittekind, G Tusch.   

Abstract

Surgical therapy offers the only chance for long-term cure of patients with hepatocellular carcinoma. The role of partial and total hepatectomy with subsequent liver replacement was analyzed in a consecutive series of 198 patients. It was the aim of this study to compare both treatment modalities on the basis of various clinicopathological prognostic factors including the TNM system of pathological classification. One hundred thirty-one resections and 61 transplantations were performed for the following histological diagnoses: hepatocellular carcinoma without coexisting liver disease (86) or associated with various hepatic abnormalities (79), fibrolamellar carcinoma (19), and mixed hepatocholangiocellular carcinoma (8). Overall actuarial survival rates at 5 years were 35.8% following resection and 15.2% after transplantation, respectively. For partial hepatectomy, factors significantly associated with improved long-term outcome were: age 30-50 years, hepatocellular carcinoma without coexisting liver disease, fibrolamellar carcinoma, solitary tumor, unilobar location, absence of vascular invasion, portal vein thrombosis or extrahepatic spread, primary tumor categories pT 2/3, stage groups II/III, and curative operation (R0). Regarding total hepatectomy, the corresponding figures were: pT2, absence of portal vein thrombosis or extrahepatic spread (negative regional lymph nodes, no distant metastases), stage group II, and curative surgery. It could be clearly shown by uni- and multivariate analyses that the pTNM classification is of clinical value regarding the assessment of prognostic significance after resection and transplantation. A group of 13 patients had secondary resection (8) or transplantation (6) for intrahepatic tumor recurrence. Whereas in all resected patients cancer recurred again, 5 of 6 transplant recipients are alive and disease-free at 12-40 months. The results of this study demonstrate that liver resection is the treatment of choice for primary liver cancer while transplantation may be indicated, especially in cases of nonresectable or recurrent lesions. Thus, the therapeutic spectrum for hepatocellular carcinoma should include both partial and total hepatectomy, being integrated into one common concept.

Entities:  

Mesh:

Year:  1991        PMID: 1851588     DOI: 10.1007/bf01659064

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  45 in total

1.  Radical resection and liver grafting as the two main components of surgical strategy in the treatment of proximal bile duct cancer.

Authors:  R Pichlmayr; B Ringe; W Lauchart; W O Bechstein; G Gubernatis; E Wagner
Journal:  World J Surg       Date:  1988-02       Impact factor: 3.352

2.  Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies.

Authors:  T E Starzl; S Todo; A Tzakis; L Podesta; L Mieles; A Demetris; L Teperman; R Selby; W Stevenson; A Stieber
Journal:  Ann Surg       Date:  1989-09       Impact factor: 12.969

3.  Prolonged survival without treatment in a patient with primary hepatocellular carcinoma.

Authors:  D Flook; L E Hughes; G T Williams
Journal:  Eur J Surg Oncol       Date:  1986-09       Impact factor: 4.424

Review 4.  Immunoradiotherapy for primary nonresectable hepatocellular carcinoma.

Authors:  J V Sitzmann; S E Order
Journal:  Surg Clin North Am       Date:  1989-04       Impact factor: 2.741

5.  Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: a retrospective comparison of 138 liver resections.

Authors:  N Nagasue; G Galizia; H Kohno; Y C Chang; T Hayashi; A Yamanoi; T Nakamura; H Yukaya
Journal:  Surgery       Date:  1989-07       Impact factor: 3.982

6.  Human liver transplantation: analysis of data on 540 patients from four centers.

Authors:  B F Scharschmidt
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

7.  Is there a place for liver grafting for malignancy?

Authors:  R Pichlmayr
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

8.  Tumor invasiveness and prognosis in resected hepatocellular carcinoma. Clinical and pathogenetic implications.

Authors:  H C Hsu; T T Wu; M Z Wu; J C Sheu; C S Lee; D S Chen
Journal:  Cancer       Date:  1988-05-15       Impact factor: 6.860

9.  Hepatocellular carcinoma: importance of histologic classification as a prognostic factor.

Authors:  W J Wood; M Rawlings; H Evans; C N Lim
Journal:  Am J Surg       Date:  1988-05       Impact factor: 2.565

10.  Experiences with liver transplantation in Hannover.

Authors:  R Pichlmayr; C Brölsch; K Wonigeit; P Neuhaus; S Siegismund; F W Schmidt; M Burdelski
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

View more
  123 in total

1.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

Review 2.  Liver resection for cancer.

Authors:  R W Parks; O J Garden
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

3.  Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence.

Authors:  Marco Vivarelli; Andrea Risaliti
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

4.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

5.  Regulation of glucose homeostasis in humans with denervated livers.

Authors:  G Perseghin; E Regalia; A Battezzati; S Vergani; A Pulvirenti; I Terruzzi; D Baratti; F Bozzetti; V Mazzaferro; L Luzi
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

6.  Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation.

Authors:  A D Pinna; S Iwatsuki; R G Lee; S Todo; J R Madariaga; J W Marsh; A Casavilla; I Dvorchik; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1997-10       Impact factor: 17.425

Review 7.  Optimizing hepatectomy for hepatocellular carcinoma in Asia-patient selection and special considerations.

Authors:  Clarence Nicholas Kotewall; Tan To Cheung
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-08

8.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

Review 9.  Management of hepatocellular cancer.

Authors:  Mary F Mulcahy
Journal:  Curr Treat Options Oncol       Date:  2005-09

10.  Predictors of survival after laparoscopic radiofrequency thermal ablation of hepatocellular cancer: a prospective study.

Authors:  E Berber; S Rogers; A Siperstein
Journal:  Surg Endosc       Date:  2005-03-11       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.